These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
273 related articles for article (PubMed ID: 26717007)
41. The epidemiologic impact and cost-effectiveness of new tuberculosis vaccines on multidrug-resistant tuberculosis in India and China. Weerasuriya CK; Harris RC; McQuaid CF; Bozzani F; Ruan Y; Li R; Li T; Rade K; Rao R; Ginsberg AM; Gomez GB; White RG BMC Med; 2021 Feb; 19(1):60. PubMed ID: 33632218 [TBL] [Abstract][Full Text] [Related]
42. How much is tuberculosis screening worth? Estimating the value of active case finding for tuberculosis in South Africa, China, and India. Azman AS; Golub JE; Dowdy DW BMC Med; 2014 Oct; 12():216. PubMed ID: 25358459 [TBL] [Abstract][Full Text] [Related]
43. Cost-effectiveness and health impact of screening and treatment of Mycobacterium tuberculosis infection among formerly incarcerated individuals in Brazil: a Markov modelling study. van Lieshout Titan A; Klaassen F; Pelissari DM; de Barros Silva JN; Alves K; Alves LC; Sanchez M; Bartholomay P; Johansen FDC; Croda J; Andrews JR; Castro MC; Cohen T; Vuik C; Menzies NA Lancet Glob Health; 2024 Sep; 12(9):e1446-e1455. PubMed ID: 39151980 [TBL] [Abstract][Full Text] [Related]
44. Cost-effectiveness of novel diagnostic tools for the diagnosis of tuberculosis. Dowdy DW; O'Brien MA; Bishai D Int J Tuberc Lung Dis; 2008 Sep; 12(9):1021-9. PubMed ID: 18713499 [TBL] [Abstract][Full Text] [Related]
45. Cost-effectiveness of adding novel or group 5 interventions to a background regimen for the treatment of multidrug-resistant tuberculosis in Germany. Wirth D; Dass R; Hettle R BMC Health Serv Res; 2017 Mar; 17(1):182. PubMed ID: 28270207 [TBL] [Abstract][Full Text] [Related]
46. Estimating a cost-effectiveness threshold for health care decision-making in South Africa. Edoka IP; Stacey NK Health Policy Plan; 2020 Jun; 35(5):546-555. PubMed ID: 32125375 [TBL] [Abstract][Full Text] [Related]
47. Cost-effectiveness of Preventive Therapy for Tuberculosis With Isoniazid and Rifapentine Versus Isoniazid Alone in High-Burden Settings. Johnson KT; Churchyard GJ; Sohn H; Dowdy DW Clin Infect Dis; 2018 Sep; 67(7):1072-1078. PubMed ID: 29617965 [TBL] [Abstract][Full Text] [Related]
48. Impact of reduced hospitalisation on the cost of treatment for drug-resistant tuberculosis in South Africa. Sinanovic E; Ramma L; Vassall A; Azevedo V; Wilkinson L; Ndjeka N; McCarthy K; Churchyard G; Cox H Int J Tuberc Lung Dis; 2015 Feb; 19(2):172-8. PubMed ID: 25574915 [TBL] [Abstract][Full Text] [Related]
49. Economic evaluation of short treatment for multidrug-resistant tuberculosis, Ethiopia and South Africa: the STREAM trial. Madan JJ; Rosu L; Tefera MG; van Rensburg C; Evans D; Langley I; Tomeny EM; Nunn A; Phillips PP; Rusen ID; Squire SB; Bull World Health Organ; 2020 May; 98(5):306-314. PubMed ID: 32514196 [TBL] [Abstract][Full Text] [Related]
50. Cost-effectiveness and total costs of three alternative strategies for the prevention and management of severe skin reactions attributable to thiacetazone in the treatment of Human Immunodeficiency Virus positive patients with tuberculosis in Kenya. van Gorkom J; Kibuga DK Tuber Lung Dis; 1996 Feb; 77(1):30-6. PubMed ID: 8733411 [TBL] [Abstract][Full Text] [Related]
51. Cost for tuberculosis care in developed countries: which data for an economic evaluation? Trieste L; Turchetti G J Rheumatol Suppl; 2014 May; 91():83-5. PubMed ID: 24789005 [TBL] [Abstract][Full Text] [Related]
52. Cost-effectiveness of tuberculosis diagnostic strategies to reduce early mortality among persons with advanced HIV infection initiating antiretroviral therapy. Abimbola TO; Marston BJ; Date AA; Blandford JM; Sangrujee N; Wiktor SZ J Acquir Immune Defic Syndr; 2012 May; 60(1):e1-7. PubMed ID: 22240465 [TBL] [Abstract][Full Text] [Related]
53. Pharmaceutical cost dynamics for the treatment of rifampicin-resistant tuberculosis in children and adolescents in South Africa, India, and the Philippines. Wilkinson T; Garcia-Prats AJ; Sachs T; Paradkar M; Suryavanshi N; Kinikar A; Frias MV; Sinanovic E; Hesseling AC; Seddon JA; Palmer M PLoS One; 2024; 19(7):e0305930. PubMed ID: 39042708 [TBL] [Abstract][Full Text] [Related]
54. Tuberculosis preventive therapy for HIV-infected people in sub-Saharan Africa is cost-effective. Bell JC; Rose DN; Sacks HS AIDS; 1999 Aug; 13(12):1549-56. PubMed ID: 10465080 [TBL] [Abstract][Full Text] [Related]
56. An epidemiological study of tuberculosis and HIV infection in Tanzania, 1991-1993. Chum HJ; O'Brien RJ; Chonde TM; Graf P; Rieder HL AIDS; 1996 Mar; 10(3):299-309. PubMed ID: 8882670 [TBL] [Abstract][Full Text] [Related]
57. Immigrant screening for latent tuberculosis in Norway: a cost-effectiveness analysis. Haukaas FS; Arnesen TM; Winje BA; Aas E Eur J Health Econ; 2017 May; 18(4):405-415. PubMed ID: 26970772 [TBL] [Abstract][Full Text] [Related]
58. Costs of tuberculosis disease in the European Union: a systematic analysis and cost calculation. Diel R; Vandeputte J; de Vries G; Stillo J; Wanlin M; Nienhaus A Eur Respir J; 2014 Feb; 43(2):554-65. PubMed ID: 23949960 [TBL] [Abstract][Full Text] [Related]
59. Cost-Effectiveness of isoniazid preventive therapy among HIV-infected patients clinicaly screened for latent tuberculosis infection in Dar es Salaam, Tanzania: A prospective Cohort study. Shayo GA; Chitama D; Moshiro C; Aboud S; Bakari M; Mugusi F BMC Public Health; 2017 Jul; 18(1):35. PubMed ID: 28724374 [TBL] [Abstract][Full Text] [Related]
60. ImPROving TB outcomes by modifying LIFE-style behaviours through a brief motivational intervention followed by short text messages (ProLife): study protocol for a randomised controlled trial. Moriarty AS; Louwagie GM; Mdege ND; Morojele N; Tumbo J; Omole OB; Bachmann MO; Kanaan M; Turner A; Parrott S; Siddiqi K; Ayo-Yusuf OA Trials; 2019 Jul; 20(1):457. PubMed ID: 31349850 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]